Cardiovascular remodeling describes the adaptive responses of myocardium and vasculature to injurious stimuli, and when it persists it can result in morphological and functional changes. Remodeling is an active process involving cell and extracellular matrix and is strongly associated with cardiometabolic diseases (CMD), such as stroke, atherosclerosis, myocardial ischemia, and diabetes mellitus. All share altered metabolism, activation of inflammatory pathways, endothelial dysfunction, micro and macro-angiopathies. Recent developments in molecular biology provide a new information on the genetics and pathways involved in remodeling. Culprit mediators include inflammation, oxidative stress, iron dyshomeostasis, mitochondrial dysfunction and autophagy dysregulation. The early-stage of remodeling in cardiometabolic diseases can be reversed, provided effective treatment is carried at the appropriate timing. Recognizing biomarker predictors of remodeling state based on molecular and gene expression data is a critical step in effective management. Furthermore, targeted therapy, aiming at selectively targeting specific pathways, can provide new hopes for treatment. A safe and effective delivery systems have also proven to play significant roles.
Despite intense research, CMD represent a global health threats attributed to their limited prediction and the lack of adequate information on the biomarkers reflecting involved pathways. Therefore, it is crucial to find valid and reliable biomarkers to be utilized in risk prediction. An effective reversal strategy should also depend on an in-depth knowledge of the underlying cellular mechanisms and should be tailored to the individual’s risk factors. Thereby, a therapeutic approach that directly targets the pathological pathways are needed. The application of targeted therapy have provided successful results in several settings both at the preclinical and clinical levels yet still not fully investigated in the field of cardiometabolic diseases. Besides, the utilization of traditional therapeutic delivery methods faces multiple challenges including low bioavailability and target specific delivery. Therefore, the use of new systems to deliver to target organs could significantly improve outcomes.
The aim of this Research Topic is to invite basic, translational research and review articles in the area of heart and vessel remodeling with special focus on novel molecular mechanisms, predictor biomarkers, novel targeting and delivery strategies.
Potential topics include but are not limited to the following:
• Information about receptors, signal transduction pathways, and identification of biomarkers that could predict cardiomyocyte and vascular remodeling in cardiometabolic diseases.
• Factors and systemic disorders that may impact pathological remodeling, and the molecular mediators in bidirectional communication between the heart and peripheral organs (brain, kidney and liver).
• Identifying novel drugs mitigating pathological remodeling and updates in different delivery systems.
• The use of mono or combined drug targeted approach to suppress signal transductions and reverse remodeling. Special focus on modulators of cytokines and toll receptor pathways.
• The use of targeted therapy and drug delivery systems to improve stem cells (and their derived microvesicles) therapeutic potentials.
Cardiovascular remodeling describes the adaptive responses of myocardium and vasculature to injurious stimuli, and when it persists it can result in morphological and functional changes. Remodeling is an active process involving cell and extracellular matrix and is strongly associated with cardiometabolic diseases (CMD), such as stroke, atherosclerosis, myocardial ischemia, and diabetes mellitus. All share altered metabolism, activation of inflammatory pathways, endothelial dysfunction, micro and macro-angiopathies. Recent developments in molecular biology provide a new information on the genetics and pathways involved in remodeling. Culprit mediators include inflammation, oxidative stress, iron dyshomeostasis, mitochondrial dysfunction and autophagy dysregulation. The early-stage of remodeling in cardiometabolic diseases can be reversed, provided effective treatment is carried at the appropriate timing. Recognizing biomarker predictors of remodeling state based on molecular and gene expression data is a critical step in effective management. Furthermore, targeted therapy, aiming at selectively targeting specific pathways, can provide new hopes for treatment. A safe and effective delivery systems have also proven to play significant roles.
Despite intense research, CMD represent a global health threats attributed to their limited prediction and the lack of adequate information on the biomarkers reflecting involved pathways. Therefore, it is crucial to find valid and reliable biomarkers to be utilized in risk prediction. An effective reversal strategy should also depend on an in-depth knowledge of the underlying cellular mechanisms and should be tailored to the individual’s risk factors. Thereby, a therapeutic approach that directly targets the pathological pathways are needed. The application of targeted therapy have provided successful results in several settings both at the preclinical and clinical levels yet still not fully investigated in the field of cardiometabolic diseases. Besides, the utilization of traditional therapeutic delivery methods faces multiple challenges including low bioavailability and target specific delivery. Therefore, the use of new systems to deliver to target organs could significantly improve outcomes.
The aim of this Research Topic is to invite basic, translational research and review articles in the area of heart and vessel remodeling with special focus on novel molecular mechanisms, predictor biomarkers, novel targeting and delivery strategies.
Potential topics include but are not limited to the following:
• Information about receptors, signal transduction pathways, and identification of biomarkers that could predict cardiomyocyte and vascular remodeling in cardiometabolic diseases.
• Factors and systemic disorders that may impact pathological remodeling, and the molecular mediators in bidirectional communication between the heart and peripheral organs (brain, kidney and liver).
• Identifying novel drugs mitigating pathological remodeling and updates in different delivery systems.
• The use of mono or combined drug targeted approach to suppress signal transductions and reverse remodeling. Special focus on modulators of cytokines and toll receptor pathways.
• The use of targeted therapy and drug delivery systems to improve stem cells (and their derived microvesicles) therapeutic potentials.